跳到主要內容

Lappe Mark 的 Form 4 申報

Inhibrx Biosciences, Inc.(INBX),2024/9/16 申報

申報編號
0002007919-24-000049
申報時間
2024/9/16
交易日
2024/9/12-9/16
申報延遲
4 天
10b5-1 計畫
沒有勾選

這份申報列了 2 筆非衍生性交易。公開市場買進合計 $62.9 萬。交易後 4 天申報。

申報人

一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。

這份申報的申報人
申報人與公司的關係
Lappe MarkCIK 0001366074董事、高階主管(執行長)

非衍生性證券(表 I)

普通股等股票的取得與處分,每一列是申報上的一筆。

非衍生性證券的交易
交易日證券交易股數價格金額交易後持股持有方式旗標
2024/9/12Common StockP買進取得+26,963$15.05F1+$405,793.15692,511間接
2024/9/16Common StockP買進取得+13,037$17.13F3+$223,323.81705,548間接

附註與備註

本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。

F1

The shares were purchased in multiple transactions at prices ranging from $15.00 to $15.10, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

表 I 有 1 筆交易的價格引用這則附註。

F3

The shares were purchased in multiple transactions at prices ranging from $16.70 to $17.695, inclusive. The reported price reflects the weighted-average purchase price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

表 I 有 1 筆交易的價格引用這則附註。

看 SEC EDGAR 上的完整原文 (在新分頁開啟)